Literature DB >> 12767379

An alternative procedure for preparation of cefdinir.

Maritza González1, Zalua Rodríguez, Blanca Tolón, Juan C Rodríguez, Hermán Velez, Bárbara Valdés, Miguel A López, Adamo Fini.   

Abstract

Cefdinir, a broad spectrum third-generation cephalosporin for oral administration, was prepared by the following synthetic pathway: synthesis of diphenylmethyl 7beta-amino-3-vinyl-3-cephem-4-carboxylate hydrochloride from 7-aminocephalosporanic acid (7-ACA), preparation of sodium 2-(2-tritylaminothiazol-4-yl)-(Z)-2-(tritylhydroxyimino) acetate from ethyl acetoacetate, coupling of both intermediaries to obtain diphenylmethyl 7beta-[2-(2-tritylaminothiazol-4-yl)-(Z)-2-tritylhydroxyimino-3-vinyl-3-cephem-4-carboxylate and final cleavage of trityl and diphenylmethyl protective groups. This procedure allows to obtain better yields of cefdinir and to avoid the use of diketene during the synthesis of this antibiotic by the previously reported method.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767379     DOI: 10.1016/S0014-827X(03)00063-6

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  4 in total

1.  Syntheses and biological evaluation of new cephalosporin-oxazolidinone conjugates.

Authors:  Shanshan Yan; Marvin J Miller; Timothy A Wencewicz; Ute Möollmann
Journal:  Medchemcomm       Date:  2010-05-05       Impact factor: 3.597

2.  Enzymatic deprotection of the cephalosporin 3'-acetoxy group using Candida antarctica lipase B.

Authors:  Leslie D Patterson; Marvin J Miller
Journal:  J Org Chem       Date:  2010-02-19       Impact factor: 4.354

3.  An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals.

Authors:  Marcus Baumann; Ian R Baxendale; Steven V Ley; Nikzad Nikbin
Journal:  Beilstein J Org Chem       Date:  2011-04-18       Impact factor: 2.883

Review 4.  Prescribed drugs containing nitrogen heterocycles: an overview.

Authors:  Majid M Heravi; Vahideh Zadsirjan
Journal:  RSC Adv       Date:  2020-12-15       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.